Check out your Company Bowl for anonymous work chats.
In our latest Investor Relations Insights video, members of our executive team sat down to recap this morning’s earnings report for the first quarter of 2024, and provide more insight into upcoming pipeline milestones, and exciting clinical and corporate developments happening at Moderna.
Moderna has been recognized on Fortune's World's Most Admired Companies list as part of its "All-Star" top-50 companies. This annual list is considered one of the leading measures of corporate reputation among global organizations.
We're proud to announce that we've received an Equality 100 score on Human Rights Campaign Foundation’s Corporate Equality Index, the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality. We celebrate our diverse workforce, and are committed to fostering a culture of belonging, inclusion and diversity in all its forms!
Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2024 Best Places to Work report for the third consecutive year. "We are proud to be named the best place to work on BioSpace's 2024 ranking for the third year in a row," said Stéphane Bancel, Chief Executive Officer of Moderna. "This recognition is a testament to the unique culture we have fostered at Moderna and the investments we have made in our remarkable team. Each day they are challenging convention and working relentlessly to get mRNA medicines to patients faster."
Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
The U.S. Food and Drug Administration (FDA) has approved our supplemental Biologics License Application (sBLA) for Spikevax® (COVID-19 Vaccine, mRNA) for individuals 12 years of age and older, which helps protect against the most dominant variants as recommended by the June 2023 FDA VRBPAC. This timely approval helps ensure everyone will have the tools they need to do their part in protecting themselves and slowing the spread of the virus as we head into the fall and winter months in the U.S.
We are IN for Disability Inclusion! We are proud to be top-scoring company on the Disability Equality Index again this year, and thank Disability:IN and the American Association of People with Disabilities for recognizing us as a Best Place to Work for Disability Inclusion.
Earlier this year, we evolved our mission to better reflect our belief that Moderna’s mRNA medicines will continue to have a profound impact on human health. We are working to deliver on our commitments to tackle some of the biggest challenges to public health, which include unequal access to quality healthcare and medicines, inequalities affecting vulnerable communities around the world, and the increasing negative effects of climate change. Our annual Environmental, Social and Governance (ESG) Report outlines our corporate social responsibility (CSR) strategy and progress aligned to five guiding focus areas for ongoing and future efforts.
Today, with the publication of our CEO Stéphane Bancel’s annual letter to shareholders, we announced the evolution of our mission. Moderna has delivered on the promise of #mRNA science. Just as our company evolves in this new age of #medicine, so too must our mission. Read the full letter: https://lnkd.in/ej8tABHn
